Delphine Topart

2.7k total citations
29 papers, 606 citations indexed

About

Delphine Topart is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Delphine Topart has authored 29 papers receiving a total of 606 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Cancer Research. Recurrent topics in Delphine Topart's work include Renal cell carcinoma treatment (11 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Delphine Topart is often cited by papers focused on Renal cell carcinoma treatment (11 papers), Cancer Genomics and Diagnostics (9 papers) and Colorectal Cancer Treatments and Studies (6 papers). Delphine Topart collaborates with scholars based in France, United States and Switzerland. Delphine Topart's co-authors include William Jacot, Kai Bartkowiak, Klaus Pantel, Thierry Fest, Delphine Rossille, Laure Cayrefourcq, Thierry Maudelondé, Martine Mazel, Catherine Alix‐Panabières and Stéphane Oudard and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and Annals of Oncology.

In The Last Decade

Delphine Topart

28 papers receiving 598 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Delphine Topart France 12 425 234 231 122 85 29 606
Emanuela Dell’Aquila Italy 12 362 0.9× 189 0.8× 242 1.0× 171 1.4× 90 1.1× 41 593
Angel Qin United States 12 343 0.8× 201 0.9× 122 0.5× 178 1.5× 94 1.1× 33 561
Amy Prawira Canada 11 326 0.8× 147 0.6× 111 0.5× 172 1.4× 94 1.1× 38 621
Caicun Zhou China 12 435 1.0× 393 1.7× 106 0.5× 197 1.6× 82 1.0× 36 710
Andrea Ravelli Italy 10 288 0.7× 251 1.1× 106 0.5× 200 1.6× 53 0.6× 15 543
Marco Puzzoni Italy 16 438 1.0× 174 0.7× 159 0.7× 213 1.7× 102 1.2× 50 737
Elisa Giommoni Italy 14 314 0.7× 180 0.8× 138 0.6× 158 1.3× 52 0.6× 45 527
Parvin F. Peddi United States 14 404 1.0× 200 0.9× 152 0.7× 206 1.7× 53 0.6× 30 661
Shan Xiong China 15 464 1.1× 350 1.5× 140 0.6× 148 1.2× 175 2.1× 49 778
Caterina Fontanella Italy 13 375 0.9× 196 0.8× 139 0.6× 145 1.2× 28 0.3× 43 625

Countries citing papers authored by Delphine Topart

Since Specialization
Citations

This map shows the geographic impact of Delphine Topart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Delphine Topart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Delphine Topart more than expected).

Fields of papers citing papers by Delphine Topart

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Delphine Topart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Delphine Topart. The network helps show where Delphine Topart may publish in the future.

Co-authorship network of co-authors of Delphine Topart

This figure shows the co-authorship network connecting the top 25 collaborators of Delphine Topart. A scholar is included among the top collaborators of Delphine Topart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Delphine Topart. Delphine Topart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Thibault, Constance, Loı̈c Mourey, Dominique Pasquier, et al.. (2025). OCTOPUS: A retrospective, multicenter study of real-world cabozantinib treatment of patients with advanced renal cell carcinoma in France—Subgroup analyses of treatment sequences and optimization.. Journal of Clinical Oncology. 43(5_suppl). 472–472. 1 indexed citations
2.
Vendrell, Julie A., Isabelle Solassol, Simon Cabello‐Aguilar, et al.. (2023). Differential Sensitivity of Germline and Somatic BRCA Variants to PARP Inhibitor in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences. 24(18). 14181–14181. 4 indexed citations
3.
Joly, Florence, Jean‐Marie Michot, Louis Marie Dourthe, et al.. (2022). Cancer du rein métastatique : gestion des toxicités des combinaisons. Bulletin du Cancer. 109(7-8). 844–861. 1 indexed citations
4.
Gross‐Goupil, Marine, Aude Fléchon, Loı̈c Mourey, et al.. (2021). 670P Cabozantinib associated with concomitant radiotherapy or a bone targeted agent (multimodal approach, results from the CABOREAL study post-hoc analysis). Annals of Oncology. 32. S694–S695. 1 indexed citations
5.
Gross‐Goupil, Marine, Aude Fléchon, Loı̈c Mourey, et al.. (2020). 722P Cabozantinib in elderly patients: Results from a subanalysis of the CABOREAL study. Annals of Oncology. 31. S566–S567. 4 indexed citations
6.
Dalban, Cécile, Brigitte Laguerre, Sylvain Ladoire, et al.. (2020). 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial. Annals of Oncology. 31. S560–S561. 1 indexed citations
7.
8.
Albigès, Laurence, Aude Fléchon, Christine Chevreau, et al.. (2020). Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program. European Journal of Cancer. 142. 102–111. 39 indexed citations
9.
Fléchon, Aude, Christine Chevreau, Delphine Topart, et al.. (2020). 732P Cabozantinib in non-clear cell metastatic renal cell carcinoma and sarcomatoid renal cell carcinoma: Real-world data from the CABOREAL study. Annals of Oncology. 31. S572–S573. 3 indexed citations
10.
Lelièvre, Loïc, Philippe Clézardin, Laurent Magaud, et al.. (2018). Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer. 18(6). e1311–e1321. 8 indexed citations
11.
Joly, Florence, Aline Guillot, Yann Vano, et al.. (2017). Enquête nationale française sur les appels téléphoniques entrants en oncologie médicale. Bulletin du Cancer. 104(6). 565–573. 1 indexed citations
12.
Jacot, William, Nelly Firmin, Lise Roca, et al.. (2016). Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxyvitamin D levels in early breast cancer patients: a randomized phase III study. Annals of Oncology. 27(7). 1235–1241. 24 indexed citations
13.
Mazel, Martine, William Jacot, Klaus Pantel, et al.. (2015). Frequent expression of PD‐L1 on circulating breast cancer cells. Molecular Oncology. 9(9). 1773–1782. 310 indexed citations
14.
Houédé, Nadine, Philippe Beuzeboc, Sophie Gourgou, et al.. (2015). Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France. BMC Cancer. 15(1). 222–222. 16 indexed citations
15.
Azria, D., Christophe Massard, Diégo Tosi, et al.. (2012). An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.. Journal of Clinical Oncology. 30(5_suppl). 149–149. 19 indexed citations
16.
Bège, Thierry, Bernard Lelong, F. Viret, et al.. (2009). Bevacizumab-Related Surgical Site Complication Despite Primary Tumor Resection in Colorectal Cancer Patients. Annals of Surgical Oncology. 16(4). 856–860. 25 indexed citations
17.
18.
Viret, F., D. Lepillé, Laurent Mineur, et al.. (2004). Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: Final results of a multicenter randomized phase II study. Journal of Clinical Oncology. 22(14_suppl). 4118–4118. 17 indexed citations
19.
20.
Jourdan, Éric, et al.. (2003). Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder. Leukemia & lymphoma. 44(5). 889–890. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Emanuela Dell’Aquila Breakdown of academic impact, for papers by Angel Qin Breakdown of academic impact, for papers by Amy Prawira Breakdown of academic impact, for papers by Caicun Zhou Breakdown of academic impact, for papers by Andrea Ravelli Breakdown of academic impact, for papers by Marco Puzzoni Breakdown of academic impact, for papers by Elisa Giommoni Breakdown of academic impact, for papers by Parvin F. Peddi Breakdown of academic impact, for papers by Shan Xiong Breakdown of academic impact, for papers by Caterina Fontanella
Rankless by CCL
2026